2007
Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users
Mehta S, Lucas G, Astemborski J, Kirk G, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007, 19: 637-645. PMID: 17505924, DOI: 10.1080/09540120701235644.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyRisk of progressionVirologic responseTreatment interruptionImmunologic responseAntiretroviral therapyCommunity-based injection drug usersDrug usersMultiple Cox regression analysisRecent outpatient visitYears of HAARTCox regression analysisInjection drug useNew AIDS diagnosesSubsequent disease progressionEarly responseHAART initiationHAART initiatorsHIV careOutpatient visitsCox regressionPrognostic valueAIDS diagnosisPoor response
2000
Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART
Carrieri M, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y, Group T. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug And Alcohol Dependence 2000, 60: 51-54. PMID: 10821989, DOI: 10.1016/s0376-8716(00)80007-1.Peer-Reviewed Original ResearchConceptsEfficacy of HAARTDrug usersBuprenorphine substitution treatmentViral load trendsActive antiretroviral therapyFrench cohort studyHIV viral loadUse of buprenorphineInjection drug usersVirologic responseAntiretroviral therapyCohort studyBuprenorphine treatmentTreatment initiationViral loadMaintenance treatmentPotential confoundersHAARTSubstitution treatmentBuprenorphineHIVIndividual treatmentPatientsTreatmentLinear regression models